Skip to main content

Advertisement

Table 2 The list of 100 most cited cannabis and cannabinoid-related manuscripts

From: Molecular neuroscience at its “high”: bibliometric analysis of the most cited papers on endocannabinoid system, cannabis and cannabinoids

Rank Reference Impact Factor 2017 Total citation count Adjusted citation count
1 Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., ... & Mechoulam, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258 (5090), 1946–1949. 41.058 3651 140.4
2 Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346 (6284), 561–564. 41.577 3345 119.5
3 Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365 (6441), 61–65. 41.577 3123 124.9
4 Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., ... & Pertwee, R. G. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology, 50 (1), 83–90. 4.235 1743 75.8
5 Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., ... & Mechoulam, R. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews, 54 (2), 161–202. 18.964 1651 103.2
6 Devane, W. A., Dysarz, F. 3., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988). Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology, 34 (5), 605–613. 3.978 1603 53.4
7 Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H. H., Sørgård, M., Di Marzo, V., ... & Högestätt, E. D. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature, 400 (6743), 452–457. 41.577 1534 80.7
8 Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., De Costa, B. R., & Rice, K. C. (1990). Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences, 87 (5), 1932–1936. 9.504 1483 53.0
9 Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., ... & Ferrara, P. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters, 350 (2–3), 240–244. 2.999 1421 59.2
10 Herkenham, M., Lynn, A. B., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. Journal of Neuroscience, 11 (2), 563–583. 5.971 1395 51.7
11 Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature, 384 (6604), 83–87. 41.577 1379 62.7
12 Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., ... & Waku, K. (1995). 2-Arachidonoylgylcerol: a possible endogenous cannabinoid receptor ligand in brain. Biochemical and Biophysical Research Communications, 215 (1), 89–97. 2.559 1347 58.6
13 Mountjoy, K. G., Robbins, L. S., Mortrud, M. T., & Cone, R. D. (1992). The cloning of a family of genes that encode the melanocortin receptors. Science, 257 (5074), 1248–1251. 41.058 1282 49.3
14 Piomelli, D. (2003). The molecular logic of endocannabinoid signalling. Nature Reviews Neuroscience, 4 (11), 873–884. 32.635 1228 81.9
15 Jordt, S. E., Bautista, D. M., Chuang, H. H., McKemy, D. D., Zygmunt, P. M., Högestätt, E. D., ... & Julius, D. (2004). Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature, 427 (6971), 260–265. 41.577 1131 80.8
16 Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J. C., & Piomelli, D. (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature, 372 (6507), 686–691. 41.577 1115 46.5
17 Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. The Lancet, 370 (9584), 319–328. 53.254 1096 99.6
18 Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., ... & Di Marzo, V. (2002). The endogenous cannabinoid system controls extinction of aversive memories. Nature, 418 (6897), 530–534. 41.577 1075 67.2
19 Tsou, K., Brown, S., Sanudo-Pena, M. C., Mackie, K., & Walker, J. M. (1998). Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience, 83 (2), 393–411. 3.382 1066 53.3
20 Pacher, P., Bátkai, S., & Kunos, G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews, 58 (3), 389–462. 18.964 1063 88.6
21 Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Bátkai, S., Járai, Z., ... & Kunos, G. (2001). Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature, 410 (6830), 822–825. 41.577 1039 61.1
22 Pertwee, R. G. (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology & Therapeutics, 74 (2), 129–180. 10.376 1030 49.0
23 Van Gaal, L. F., Rissanen, A. M., Scheen, A. J., Ziegler, O., Rössner, S., & RIO-Europe Study Group. (2005). Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. The Lancet, 365 (9468), 1389–1397. 53.254 1024 78.8
24 Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., ... & Giustino, A. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nature Medicine, 9 (1), 76–81. 32.621 1016 67.7
25 Stella, N., Schweitzer, P., & Piomelli, D. (1997). A second endogenous cannabinoid that modulates long-term potentiation. Nature, 388 (6644), 773–778. 41.577 1002 47.7
26 Wilson, R. I., & Nicoll, R. A. (2001). Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature, 410 (6828), 588–592. 41.577 996 58.6
27 Després, J. P., Golay, A., & Sjöström, L. (2005). Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New England Journal of Medicine, 353 (20), 2121–2134. 79.26 968 74.5
28 Freund, T. F., Katona, I., & Piomelli, D. (2003). Role of endogenous cannabinoids in synaptic signaling. Physiological Reviews, 83 (3), 1017–1066. 24.014 965 64.3
29 Galiègue, S., Mary, S., Marchand, J., Dussossoy, D., Carrière, D., Carayon, P., ... & Casellas, P. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. European Journal of Biochemistry, 232 (1), 54–61. 4.53 963 41.9
30 Ledent, C., Valverde, O., Cossu, G., Petitet, F., Aubert, J. F., Beslot, F., ... & Vassart, G. (1999). Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science, 283 (5400), 401–404. 41.058 928 48.8
31 Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proceedings of the National Academy of Sciences, 98 (16), 9371–9376. 9.504 905 53.2
32 Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J. P., Druart, C., Bindels, L. B., ... & De Vos, W. M. (2013). Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proceedings of the National Academy of Sciences, 110 (22), 9066–9071. 9.504 876 175.2
33 Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., ... & Marnett, L. J. (2005). Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science, 310 (5746), 329–332. 41.058 861 66.2
34 Pi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Devin, J., Rosenstock, J., & RIO-North America Study Group. (2006). Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA, 295 (7), 761–775. 47.661 850 70.8
35 Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., ... & Piomelli, D. (2002). Brain monoglyceride lipase participating in endocannabinoid inactivation. Proceedings of the National Academy of Sciences, 99 (16), 10,819–10,824. 9.504 807 50.4
36 Wilson, R. I., & Nicoll, R. A. (2002). Endocannabinoid signaling in the brain. Science, 296 (5568), 678–682. 41.058 799 49.9
37 Cota, D., Marsicano, G., Tschöp, M., Grübler, Y., Flachskamm, C., Schubert, M., ... & Tomassoni, F. (2003). The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. The Journal of Clinical Investigation, 112 (3), 423–431. 13.251 786 52.4
38 Caspi, A., Moffitt, T. E., Cannon, M., McClay, J., Murray, R., Harrington, H., ... & Poulton, R. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biological Psychiatry, 57 (10), 1117–1127. 11.984 784 60.3
39 Calignano, A., La Rana, G., Giuffrida, A., & Piomelli, D. (1998). Control of pain initiation by endogenous cannabinoids. Nature, 394 (6690), 277–281. 41.577 782 39.1
40 Katona, I., Sperlágh, B., Sı́k, A., Käfalvi, A., Vizi, E. S., Mackie, K., & Freund, T. F. (1999). Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. Journal of Neuroscience, 19 (11), 4544–4558. 5.971 761 40.1
41 Tanda, G., Pontieri, F. E., & Di Chiara, G. (1997). Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common μ1 opioid receptor mechanism. Science, 276 (5321), 2048–2050. 41.058 731 34.8
42 Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., ... & López-Rodríguez, M. L. (2003). CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science, 302 (5642), 84–88. 41.058 724 48.3
43 Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M., & Bonner, T. I. (1999). Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proceedings of the National Academy of Sciences, 96 (10), 5780–5785. 9.504 721 37.9
44 Osei-Hyiaman, D., DePetrillo, M., Pacher, P., Liu, J., Radaeva, S., Bátkai, S., ... & Kunos, G. (2005). Endocannabinoid activation at hepatic CB 1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. The Journal of Clinical Investigation, 115 (5), 1298–1305. 13.251 710 54.6
45 Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, M. R., ... & Mechoulam, R. (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacological Reviews, 62 (4), 588–631. 18.964 709 88.6
46 Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009). Endocannabinoid-mediated control of synaptic transmission. Physiological Reviews, 89 (1), 309–380. 24.014 692 76.9
47 Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002). Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ, 325 (7374), 1212–1213. 23.562 690 43.1
48 Suzuki, A., Josselyn, S. A., Frankland, P. W., Masushige, S., Silva, A. J., & Kida, S. (2004). Memory reconsolidation and extinction have distinct temporal and biochemical signatures. Journal of Neuroscience, 24 (20), 4787–4795. 5.971 681 48.6
49 Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N. O., Leonova, J., ... & Greasley, P. J. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology, 152 (7), 1092–1101. 6.81 679 61.7
50 Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., ... & Kamerman, P. R. (2015). Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. The Lancet Neurology, 14 (2), 162–173. 27.144 639 213.0
51 Andréasson, S., Engström, A., Allebeck, P., & Rydberg, U. (1987). Cannabis and schizophrenia A longitudinal study of Swedish conscripts. The Lancet, 330 (8574), 1483–1486. 53.254 632 20.4
52 Wise, R. A. (1996). Neurobiology of addiction. Current Opinion in Neurobiology, 6 (2), 243–251. 6.541 623 28.3
53 van Os, J., Kenis, G., & Rutten, B. P. (2010). The environment and schizophrenia. Nature, 468 (7321), 203–212. 41.577 615 76.9
54 Bisogno, T., Howell, F., Williams, G., Minassi, A., Cascio, M. G., Ligresti, A., ... & Gangadharan, U. (2003). Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. Journal of Cell Biology, 163 (3), 463–468. 8.784 608 40.5
55 Tchernof, A., & Després, J. P. (2013). Pathophysiology of human visceral obesity: an update. Physiological Reviews, 93 (1), 359–404. 24.014 602 120.4
56 Watanabe, H., Vriens, J., Prenen, J., Droogmans, G., Voets, T., & Nilius, B. (2003). Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature, 424 (6947), 434–438. 41.577 597 39.8
57 Beltramo, M., Stella, N., Calignano, A., Lin, S. Y., Makriyannis, A., & Piomelli, D. (1997). Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science, 277 (5329), 1094–1097. 41.058 595 28.3
58 Millan, M. J. (2003). The neurobiology and control of anxious states. Progress in Neurobiology, 70 (2), 83–244. 14.163 581 38.7
59 Di Marzo, V., Bifulco, M., & De Petrocellis, L. (2004). The endocannabinoid system and its therapeutic exploitation. Nature Reviews Drug Discovery, 3 (9), 771–784. 50.167 580 41.4
60 Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. (2014). Adverse health effects of marijuana use. New England Journal of Medicine, 370 (23), 2219–2227. 79.26 577 144.3
61 Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007). Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. The Lancet, 370 (9600), 1706–1713. 53.254 568 51.6
62 Felder, C. C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., ... & Mitchell, R. L. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Molecular Pharmacology, 48 (3), 443–450. 3.978 568 24.7
63 Wise, R. A. (1996). Addictive drugs and brain stimulation reward. Annual Review of Neuroscience, 19 (1), 319–340. 14.675 567 25.8
64 Deutsch, D. G., & Chin, S. A. (1993). Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochemical Pharmacology, 46 (5), 791–796. 4.235 567 22.7
65 Kreitzer, A. C., & Regehr, W. G. (2001). Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron, 29 (3), 717–727. 14.319 564 33.2
66 Ohno-Shosaku, T., Maejima, T., & Kano, M. (2001). Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron, 29 (3), 729–738. 14.319 560 32.9
67 Blankman, J. L., Simon, G. M., & Cravatt, B. F. (2007). A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chemistry & Biology, 14 (12), 1347–1356. 5.915 556 50.5
68 Giuffrida, A., Parsons, L. H., Kerr, T. M., De Fonseca, F. R., Navarro, M., & Piomelli, D. (1999). Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nature Neuroscience, 2 (4), 358–363. 19.912 553 29.1
69 Mackie, K., & Hille, B. (1992). Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proceedings of the National Academy of Sciences, 89 (9), 3825–3829. 9.504 551 21.2
70 Smart, D., Gunthorpe, M. J., Jerman, J. C., Nasir, S., Gray, J., Muir, A. I., ... & Davis, J. B. (2000). The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). British Journal of Pharmacology, 129 (2), 227–230. 6.81 548 30.4
71 Arseneault, L., Cannon, M., Witton, J., & Murray, R. M. (2004). Causal association between cannabis and psychosis: examination of the evidence. The British Journal of Psychiatry, 184 (2), 110–117. 5.867 547 39.1
72 Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, J. M., Casellas, P., Congy, C., ... & Portier, M. (1998). SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. Journal of Pharmacology and Experimental Therapeutics, 284 (2), 644–650. 3.706 536 26.8
73 Long, J. Z., Li, W., Booker, L., Burston, J. J., Kinsey, S. G., Schlosburg, J. E., ... & Lichtman, A. H. (2009). Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nature Chemical Biology, 5 (1), 37–44. 13.843 533 59.2
74 Dewey, W. L. (1986). Cannabinoid pharmacology. Pharmacological Reviews, 38 (2), 151–178. 18.964 530 16.6
75 Ameri, A. (1999). The effects of cannabinoids on the brain. Progress in Neurobiology, 58 (4), 315–348. 14.163 520 27.4
76 Hesselbrock, M., Easton, C., Bucholz, K. K., Schuckit, M., & Hesselbrock, V. (1999). A validity study of the SSAGA-a comparison with the SCAN. Addiction, 94 (9), 1361–1370. 6.048 519 27.3
77 Glass, M., Faull, R. L. M., & Dragunow, M. (1997). Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 77 (2), 299–318. 3.382 519 24.7
78 Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 153 (2), 199–215. 6.81 512 51.2
79 Pagotto, U., Marsicano, G., Cota, D., Lutz, B., & Pasquali, R. (2005). The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrine Reviews, 27 (1), 73–100. 15.545 512 42.7
80 Breslau, N., Kilbey, M. M., & Andreski, P. (1991). Nicotine dependence, major depression, and anxiety in young adults. Archives of General Psychiatry, 48 (12), 1069–1074. 16.642 512 19.0
81 Scheen, A. J., Finer, N., Hollander, P., Jensen, M. D., Van Gaal, L. F., & RIO-Diabetes Study Group. (2006). Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. The Lancet, 368 (9548), 1660–1672. 53.254 507 42.3
82 Marsicano, G., & Lutz, B. (1999). Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. European Journal of Neuroscience, 11 (12), 4213–4225. 2.832 505 26.6
83 Mailleux, P., & Vanderhaeghen, J. J. (1992). Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience, 48 (3), 655–668. 3.382 504 19.4
84 Van Os, J., Bak, M., Hanssen, M., Bijl, R. V., De Graaf, R., & Verdoux, H. (2002). Cannabis use and psychosis: a longitudinal population-based study. American Journal of Epidemiology, 156 (4), 319–327. 4.322 503 31.4
85 Kirkham, T. C., Williams, C. M., Fezza, F., & Marzo, V. D. (2002). Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. British Journal of Pharmacology, 136 (4), 550–557. 6.81 502 31.4
86 Hanuš, L., Abu-Lafi, S., Fride, E., Breuer, A., Vogel, Z., Shalev, D. E., ... & Mechoulam, R. (2001). 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proceedings of the National Academy of Sciences, 98 (7), 3662–3665. 9.504 499 29.4
87 Facci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, S. D., & Leon, A. (1995). Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proceedings of the National Academy of Sciences, 92 (8), 3376–3380. 9.504 499 21.7
88 Gerard, C. M., Mollereau, C., Vassart, G., & Parmentier, M. (1991). Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochemical Journal, 279 (1), 129–134. 3.857 497 18.4
89 Di Marzo, V. (2008). Targeting the endocannabinoid system: to enhance or reduce? Nature Reviews Drug Discovery, 7 (5), 438–455. 50.167 494 49.4
90 Degenhardt, L., & Hall, W. (2012). Extent of illicit drug use and dependence, and their contribution to the global burden of disease. The Lancet, 379 (9810), 55–70. 53.254 492 82.0
91 Grant, B. F., Saha, T. D., Ruan, W. J., Goldstein, R. B., Chou, S. P., Jung, J., ... & Hasin, D. S. (2016). Epidemiology of DSM-5 drug use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions–III. JAMA Psychiatry, 73 (1), 39–47. 16.642 491 245.5
92 Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanuš, L., Breuer, A., Mechoulam, R., & Shohami, E. (2001). An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature, 413 (6855), 527–531. 41.577 488 28.7
93 Hall, W., & Degenhardt, L. (2009). Adverse health effects of non-medical cannabis use. The Lancet, 374 (9698), 1383–1391. 53.254 486 54.0
94 Okamoto, Y., Morishita, J., Tsuboi, K., Tonai, T., & Ueda, N. (2004). Molecular characterization of a phospholipase D generating anandamide and its congeners. Journal of Biological Chemistry, 279 (7), 5298–5305. 4.011 486 34.7
95 Di, S., Malcher-Lopes, R., Halmos, K. C., & Tasker, J. G. (2003). Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. Journal of Neuroscience, 23 (12), 4850–4857. 5.971 486 32.4
96 Di Marzo, V., & Matias, I. (2005). Endocannabinoid control of food intake and energy balance. Nature Neuroscience, 8 (5), 585–589. 19.912 478 36.8
97 Linszen, D. H., Dingemans, P. M., & Lenior, M. E. (1994). Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry, 51 (4), 273–279. 16.642 477 19.9
98 Chevaleyre, V., Takahashi, K. A., & Castillo, P. E. (2006). Endocannabinoid-mediated synaptic plasticity in the CNS. Annual Review of Neuroscience, 29, 37–76. 14.675 474 39.5
99 Pertwee, R. G. (2001). Cannabinoid receptors and pain. Progress in Neurobiology, 63 (5), 569–611. 14.163 472 27.8
100 Hohmann, A. G., Suplita, R. L., Bolton, N. M., Neely, M. H., Fegley, D., Mangieri, R., ... & Duranti, A. (2005). An endocannabinoid mechanism for stress-induced analgesia. Nature, 435 (7045), 1108–1112. 41.577 469 36.1
  1. Impact factor 2017 of JAMA Psychiatry is used to represent Archives of General Psychiatry, which was re-named as the former before. Similarly, impact factor 2017 of FEBS Journal is used to represent European Journal of Biochemistry
  2. Adjusted citation count is total citation count divided by years since publication